About Receptor-type tyrosine-protein phosphatase mu
Receptor-type tyrosine-protein phosphatase mu (PTPRM) is a protein
from Homo sapiens identified by UniProt accession
P28827, 1452 residues long.
MolForge cross-references it against 0 known binders and
102 disease associations.
Target properties
| Protein name | Receptor-type tyrosine-protein phosphatase mu |
| UniProt accession | P28827 |
| Gene | PTPRM |
| Organism | Homo sapiens |
| Length | 1452 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (102)
Diseases linked to this target (Open Targets).
- body height · score 0.45
- body mass index · score 0.42
- FEV/FVC ratio · score 0.33
- heel bone mineral density · score 0.31
- brain measurement · score 0.30
- obesity · score 0.30
- neurodegenerative disease · score 0.30
- DNA methylation · score 0.26
- gut microbiome measurement · score 0.25
- bone density · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P28827-F1 | alphafold | PREDICTED | 83.94 | — |
Amino-acid sequence (1452 residues)
MRGLGTCLAT LAGLLLTAAG ETFSGGCLFD EPYSTCGYSQ SEGDDFNWEQ VNTLTKPTSD PWMPSGSFML VNASGRPEGQ RAHLLLPQLK ENDTHCIDFH YFVSSKSNSP PGLLNVYVKV NNGPLGNPIW NISGDPTRTW NRAELAISTF WPNFYQVIFE VITSGHQGYL AIDEVKVLGH PCTRTPHFLR IQNVEVNAGQ FATFQCSAIG RTVAGDRLWL QGIDVRDAPL KEIKVTSSRR FIASFNVVNT TKRDAGKYRC MIRTEGGVGI SNYAELVVKE PPVPIAPPQL ASVGATYLWI QLNANSINGD GPIVAREVEY CTASGSWNDR QPVDSTSYKI GHLDPDTEYE ISVLLTRPGE GGTGSPGPAL RTRTKCADPM RGPRKLEVVE VKSRQITIRW EPFGYNVTRC HSYNLTVHYC YQVGGQEQVR EEVSWDTENS HPQHTITNLS PYTNVSVKLI LMNPEGRKES QELIVQTDED LPGAVPTESI QGSTFEEKIF LQWREPTQTY GVITLYEITY KAVSSFDPEI DLSNQSGRVS KLGNETHFLF FGLYPGTTYS FTIRASTAKG FGPPATNQFT TKISAPSMPA YELETPLNQT DNTVTVMLKP AHSRGAPVSV YQIVVEEERP RRTKKTTEIL KCYPVPIHFQ NASLLNSQYY FAAEFPADSL QAAQPFTIGD NKTYNGYWNT PLLPYKSYRI YFQAASRANG ETKIDCVQVA TKGAATPKPV PEPEKQTDHT VKIAGVIAGI LLFVIIFLGV VLVMKKRKLA KKRKETMSST RQEMTVMVNS MDKSYAEQGT NCDEAFSFMD THNLNGRSVS SPSSFTMKTN TLSTSVPNSY YPDETHTMAS DTSSLVQSHT YKKREPADVP YQTGQLHPAI RVADLLQHIT QMKCAEGYGF KEEYESFFEG QSAPWDSAKK DENRMKNRYG NIIAYDHSRV RLQTIEGDTN SDYINGNYID GYHRPNHYIA TQGPMQETIY DFWRMVWHEN TASIIMVTNL VEVGRVKCCK YWPDDTEIYK DIKVTLIETE LLAEYVIRTF AVEKRGVHEI REIRQFHFTG WPDHGVPYHA TGLLGFVRQV KSKSPPSAGP LVVHCSAGAG RTGCFIVIDI MLDMAEREGV VDIYNCVREL RSRRVNMVQT EEQYVFIHDA ILEACLCGDT SVPASQVRSL YYDMNKLDPQ TNSSQIKEEF RTLNMVTPTL RVEDCSIALL PRNHEKNRCM DILPPDRCLP FLITIDGESS NYINAALMDS YKQPSAFIVT QHPLPNTVKD FWRLVLDYHC TSVVMLNDVD PAQLCPQYWP ENGVHRHGPI QVEFVSADLE EDIISRIFRI YNAARPQDGY RMVQQFQFLG WPMYRDTPVS KRSFLKLIRQ VDKWQEEYNG GEGRTVVHCL NGGGRSGTFC AISIVCEMLR HQRTVDVFHA VKTLRNNKPN MVDLLDQYKF CYEVALEYLN SG
Explore Receptor-type tyrosine-protein phosphatase mu with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets